XERS at a glance
Xeris Biopharma Holdings, Inc. (XERS, SEC CIK 1867096) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Xeris Biopharma Holdings, Inc. (XERS) reported revenue of $291.8 million (up 43.7% from FY2024) and net income of $554,000. Diluted EPS was $0.00.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Xeris Biopharma Holdings, Inc. (XERS) shares worth $529.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by McCulloch Kevin on November 5, 2026 of 25,000 shares at $12.49 per share.
- In the last 90 days, XERS insiders reported 0 open-market purchases ($0) and 11 open-market sales ($1.7M) on Form 4, a net sale of $1.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $291.8M
- +43.7% vs prior year
- Insiders · 90 days
- 0 buys · 11 sells
- Net −$1.7M
- 13F holders
- 29 funds
- $529.3M · +0 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Commercial-stage biopharma focused on therapies for chronic endocrine and neurological diseases in the U.S., with three commercial products: Recorlev, Gvoke, Keveyis
- Phase 3-ready XP-8121: once-weekly subcutaneous levothyroxine injection leveraging proprietary XeriSol tech, planned Phase 3 start in 2026
- Strategic emphasis on pipeline leveraging proprietary non-aqueous formulation tech (XeriSol/XeriJect) for improved drug delivery and new licensing partnerships
- Patent protection for key products: Recorlev (orphan drug exclusivity through 2028, patents to 2040), Gvoke patents to 2036; Keveyis lost orphan exclusivity in 2022, facing generic competition
- Noteworthy: Positive Phase 2 data for XP-8121 with 72% patient preference for weekly injection; FDA agreed on single non-inferiority Phase 3 trial design
Risk Factors
- Risk of SBA PPP Loan audit/enforcement under CARES Act until May 2026, potentially diverting management resources and incurring costs
- Geopolitical and macroeconomic risks impairing capital access due to inflation, interest rates, bank failures, and financial market volatility
- Supply chain and inventory risks with potential product returns exceeding reserves, reliant on third-party data accuracy for return estimates
- Competitive threats to Recorlev from Corcept Therapeutics' Korlym, Recordati's Signifor LAR and Isturisa, and potential ketoconazole approval in US
- Financial risk from $200M term loans and $33.6M 8.00% Convertible Notes secured by company assets, with restrictive covenants limiting operations
Management Discussion & Analysis
- Financing cash inflow $11.4M in 2025 vs $36.2M in 2024; driven by $20.7M stock awards and $10.9M stock repurchases
- Investing cash outflow $696K in 2025 vs inflow $4.9M in 2024 due to fewer short-term investment purchases
AI summary of the XERS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors since the December 31, 2025 Form 10-K
- Carried-forward business risks could materially affect operations and consolidated financial statements
- Carried-forward risks could adversely affect results of operations and cash flows
- Unknown or currently immaterial risks could impair business operations
Management Discussion & Analysis
- Total revenue $107.2M, up 44.2% YoY from $74.4M
- Operating margin 15.8% vs 9.0% YoY, net income $11.3M vs $0.6M
- Best performer Recorlev: $71.5M, up 93.5%; weakest Gvoke: $21.7M, down 13.7%
- Operating cash flow $53.6M vs $8.6M; financing cash outflow $32.9M, including $23.1M debt settlement
- Cash resources sufficient for at least twelve months, with potential future financing needs and ongoing net losses ahead
AI summary of the XERS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month 2026 operating results and business highlights announced for periods ended September 30, 2026
- Investor-relevant financial details and management commentary contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 revenue $107.2M, up 44% YoY, led by Recorlev revenue $71.5M, up 93%
- Gross margin reached 88% versus 85%, while adjusted EBITDA increased to $30.8M from $17.4M
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 8 to 9 directors, adding Menassie Taddese effective November 2, 2026
- Taddese brings Pfizer and Viatris emerging-markets and finance experience, potentially supporting international growth strategy
Item 7.01: Regulation FD Disclosure
- Taddese appointed to Xeris Biopharma’s Board of Directors
- Board refresh may influence governance, strategic oversight and shareholder confidence
Item EX-99.1: Item EX-99.1
- Menassie M. Taddese appointed director effective November 2, 2026
- Audit Committee appointment strengthens board financial oversight and governance expertise
Item 8.01: Other Events
- Xeris filed two patent infringement lawsuits against generic dichlorphenamide manufacturers and specialty pharmacies
- Litigation follows grant of U.S. Patent No. 12,758,502 covering KEVEYIS®, supporting protection against generic competition
AI summaries of XERS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for XERS
Don't miss the next XERS filing
- Alerts as it files. A push when XERS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut XERS, by share count.
- Ask anything. An AI agent that reads every XERS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| McCulloch Kevin | Sell | Nov 5, 2026 | 25,000 | $12.49 |
| McCulloch Kevin | Sell | Nov 2, 2026 | 15,000 | $10.23 |
| Pieper Steven | Sell | Nov 2, 2026 | 5,000 | $10.23 |
| Taddese Menassie | A | Nov 2, 2026 | 22,365 | - |
| Hecht Beth | Sell | Nov 2, 2026 | 25,000 | $10.23 |
| Taddese Menassie | A | Nov 2, 2026 | 31,499 | $10.17 |
| McCulloch Kevin | Sell | Oct 1, 2026 | 15,000 | $9.41 |
| Hecht Beth | Sell | Oct 1, 2026 | 16,666 | $9.41 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $203.1M | $291.8M |
| Operating Income | -$44.0M | -$33.6M | $24.9M |
| Net Income | -$62.3M | -$54.8M | $554K |
| Op. Margin | - | -16.6% | 8.5% |
| Net Margin | - | -27.0% | 0.2% |
| Balance Sheet | |||
| Total Assets | $322.6M | $323.1M | $383.5M |
| Equity | -$6.8M | -$29.6M | $13.7M |
| ROE | 917.9% | 185.2% | 4.0% |
| Per Share | |||
| EPS | $-0.45 | $-0.37 | $0.00 |
| Cash Flow | |||
| Operating CF | -$47.0M | -$37.0M | $28.6M |
Source: XBRL data in Xeris Biopharma Holdings, Inc. (XERS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate XERS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $529.3M |
| Q2 2026 | 29 | $419.2M |
| Q1 2026 | 28 | $295.5M |
| Q4 2025 | 25 | $392.2M |
| Q3 2025 | 26 | $407.6M |
| Q2 2025 | 26 | $231.0M |
| Q1 2025 | 24 | $207.8M |
| Q4 2024 | 18 | $69.6M |
- JPMorgan Chase & Co+1.32M (+125%)
- State Street Corp+753.0K (+16%)
- Dimensional Fund Advisors+621.9K (+58%)
- Citigroup+406.1K (+302%)
- Vanguard Capital Management LLC+370.1K (+5%)
- Two Sigma Investments−673.6K (-36%)
- Citadel Advisors LLC−495.3K (-75%)
- Bank of America Corp−338.5K (-24%)
- Wells Fargo & Co−104.4K (-66%)
- Franklin Resources−14.8K (-17%)
- StoneX Group Inc.+14.8K
- Fifth Third Bancorp+265
- FMR LLC (Fidelity)−644.1K
- Renaissance Technologies LLC−67.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 205 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
XERS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 6, 2026 | - | - | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| SC 13G | Jul 31, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
XERS SEC filings: frequently asked questions
Are XERS insiders buying or selling?
In the last 90 days, Xeris Biopharma Holdings, Inc. (XERS) officers, directors and 10% owners reported no open-market purchases and 11 open-market sales worth $1.7 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold XERS stock?
As of September 30, 2026, the largest Xeris Biopharma Holdings, Inc. (XERS) holders among the 13F filers tracked by SignalX were BlackRock ($140.1 million), D.E. Shaw & Co ($76.3 million), Vanguard Capital Management LLC ($73.7 million), State Street Corp ($53.3 million), Vanguard Portfolio Management LLC ($25.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was XERS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Xeris Biopharma Holdings, Inc. (XERS) reported revenue of $291.8 million (up 43.7% from FY2024) and net income of $554,000. Diluted EPS was $0.00. The figures come from the XBRL data in the 10-K.
What are the main risks in XERS's latest 10-K?
In the 10-K filed March 2, 2026, Xeris Biopharma Holdings, Inc. (XERS) flagged: Risk of SBA PPP Loan audit/enforcement under CARES Act until May 2026, potentially diverting management resources and incurring costs. Geopolitical and macroeconomic risks impairing capital access due to inflation, interest rates, bank failures, and financial market volatility. (AI summary of the Risk Factors section.)
What did XERS report in its latest 8-K?
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 and nine-month 2026 operating results and business highlights announced for periods ended September 30, 2026.
What are the latest XERS SEC filings?
Xeris Biopharma Holdings, Inc. (XERS) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 6, 2026.
What is XERS's SEC CIK number?
Xeris Biopharma Holdings, Inc. (XERS)'s SEC Central Index Key (CIK) is 1867096. EDGAR lists every XERS filing under that number.
Ask anything about XERS
The research agent reads XERS's filings, financials, insider trades and 13F holders, then answers with sources.